UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis

T-Reuters2021-09-09

Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

CJS07
2021-09-10
CJS07
Prizer,s share prize is too low despite its good performance
- 维克多1:
  能赚就是福，积少成多，聚沙成塔嘛，慢慢来
- 王无所不知:
  这是正常现象啦，不是还存在高估低估的情况嘛
- 李苗苗:
  有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧
- 东营天地人和:
  确实如此，让人感到有些失望
- 河东荷西:
  这也算是正常情况吧，我就没见过哪些特别高的，高到哪去
YokeYew
2021-09-09
YokeYew
Good to see that Pfizer is doing well.

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2166310922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-09 19:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2166310922","market":"hk","top_or_hot":-1,"title":"UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis","media":"T-Reuters","content":"<html><body><p>Pfizer Inc <pfe.n>:Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..</pfe.n></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.trkd.thomsonreuters.com><strong>T-Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In ...</p>\n\n<a href=\"https://www.trkd.thomsonreuters.com\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LHDX","symbol_name":"Lucira Health, Inc.","start_time":0,"source_url":"https://www.trkd.thomsonreuters.com","article_id":"2166310922","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2166310922","pubTimestamp":1631185740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"T-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LHDX":"Lucira Health, Inc.","PFE":"辉瑞","LABP":"Landos Biopharma, Inc.","SANA":"Sana Biotechnology, Inc.","APR":"Apria, Inc.","CGEM":"Cullinan Therapeutics"},"translate_title":"英国MHRA批准辉瑞Cibinqo用于患有中度至重度特应性皮炎的成人和青少年的营销授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APR":0.9,"CGEM":0.9,"LABP":0.9,"LHDX":0.9,"PFE":0.9,"SANA":0.9},"content_text":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..","kind":"highlight","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":883890839,"gmtCreate":1631231240721,"gmtModify":1676530501050,"author":{"id":"3575236051539340","authorId":"3575236051539340","name":"CJS07","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3575236051539340","authorIdStr":"3575236051539340"},"htmlText":"Prizer,s share prize is too low despite its good performance&nbsp;","listText":"Prizer,s share prize is too low despite its good performance&nbsp;","text":"Prizer,s share prize is too low despite its good performance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/883890839","repostId":2166310922,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5830472,"gmtCreate":1631347059110,"gmtModify":1663233724137,"authorId":9000000000000212,"author":{"id":9000000000000212,"idStr":"9000000000000212","authorId":9000000000000212,"name":"维克多1","avatar":"https://static.tigerbbs.com/7d7e7dad7e3f23e1b339e01d9cc402ed","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"type":1,"supId":0,"prevId":0,"content":"能赚就是福，积少成多，聚沙成塔嘛，慢慢来","text":"能赚就是福，积少成多，聚沙成塔嘛，慢慢来","html":"能赚就是福，积少成多，聚沙成塔嘛，慢慢来"},{"id":5830469,"gmtCreate":1631347037722,"gmtModify":1663233721228,"authorId":9000000000000161,"author":{"id":9000000000000161,"idStr":"9000000000000161","authorId":9000000000000161,"name":"王无所不知","avatar":"https://static.tigerbbs.com/4ec8b377ac9ad32d941432c2e87c3f1b","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"type":1,"supId":0,"prevId":0,"content":"这是正常现象啦，不是还存在高估低估的情况嘛","text":"这是正常现象啦，不是还存在高估低估的情况嘛","html":"这是正常现象啦，不是还存在高估低估的情况嘛"},{"id":5817356,"gmtCreate":1631261281853,"gmtModify":1663233662942,"authorId":3479274710327383,"author":{"id":3479274710327383,"idStr":"3479274710327383","authorId":3479274710327383,"name":"李苗苗","avatar":"https://static.laohu8.com/picture41","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"type":1,"supId":0,"prevId":0,"content":"有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧","text":"有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧","html":"有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧"},{"id":5811814,"gmtCreate":1631232638729,"gmtModify":1663233641545,"authorId":3479274789332061,"author":{"id":3479274789332061,"idStr":"3479274789332061","authorId":3479274789332061,"name":"东营天地人和","avatar":"https://static.laohu8.com/picture133","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"type":1,"supId":0,"prevId":0,"content":"确实如此，让人感到有些失望","text":"确实如此，让人感到有些失望","html":"确实如此，让人感到有些失望"},{"id":5811843,"gmtCreate":1631232742804,"gmtModify":1663233639553,"authorId":9000000000000148,"author":{"id":9000000000000148,"idStr":"9000000000000148","authorId":9000000000000148,"name":"河东荷西","avatar":"https://static.tigerbbs.com/448be2640dd5797560f74ee9b8c8fd00","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"type":1,"supId":0,"prevId":0,"content":"这也算是正常情况吧，我就没见过哪些特别高的，高到哪去","text":"这也算是正常情况吧，我就没见过哪些特别高的，高到哪去","html":"这也算是正常情况吧，我就没见过哪些特别高的，高到哪去"}],"langContent":"EN"},{"id":883981718,"gmtCreate":1631196391334,"gmtModify":1676530493891,"author":{"id":"4088757526331130","authorId":"4088757526331130","name":"YokeYew","avatar":"https://static.tigerbbs.com/b076671cd621c58416788f1bad4c92ab","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088757526331130","authorIdStr":"4088757526331130"},"htmlText":"Good to see that Pfizer is doing well.","listText":"Good to see that Pfizer is doing well.","text":"Good to see that Pfizer is doing well.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883981718","repostId":2166310922,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":48,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2166310922"}